News - Gastro-intestinals, Forest Laboratories


Popular Filters

Forest Labs to spend $2.9 billion on acquiring Aptalis

Forest Labs to spend $2.9 billion on acquiring Aptalis


Confirming recent speculative reports, US drugmaker Forest Laboratories says it has entered into a definitive…

AptalisForest LaboratoriesGastro-intestinalsMergers & AcquisitionsPharmaceuticalRare diseases

Forest Laboratories announces new appointments to its executive team


New York-based pharmaceutical company Forest Laboratories (NYSE: FRX) has announced new appointments…

Anti-viralsBoardroomCardio-vascularCNS DiseasesForest LaboratoriesGastro-intestinalsPharmaceuticalRespiratory and PulmonaryUSA

Almirall gains rights for IBS drug linaclotide in Mexico


Spain's largest drugmaker Almirall (ALM. MC) says it has reached an agreement with USA-based Forest Laboratories…

AlmirallForest LaboratoriesGastro-intestinalsLicensinglinaclotidePharmaceuticalSouth America

FDA nod for use of Ironwood and Forest's Linzess in certain cases of IBS and constipation


The US Food and Drug Administration last week approved Linzess (linaclotide), co-marketed by US drugmakers…

Forest LaboratoriesGastro-intestinalsIronwood PharmaceuticalslinaclotideLinzessNorth AmericaPharmaceuticalRegulation

FDA extends review of Ironwood and Forest's linaclotide to September


The US Food and Drug Administration has told USA-based drugmakers Ironwood Pharmaceuticals (Nasdaq: IRWD)…

Forest LaboratoriesGastro-intestinalsIronwood PharmaceuticalslinaclotideNorth AmericaPharmaceuticalRegulation

US FDA accepts Ironwood and Forest’s NDA for IBS drug linaclotide; new data from Almirall


US drugmakers Ironwood Pharmaceuticals (Nasdaq: IRWD) and Forest Laboratories (NYSE: FRX) said yesterday…

AlmirallForest LaboratoriesGastro-intestinalsIronwood PharmaceuticalslinaclotideNorth AmericaPharmaceuticalRegulationResearch

FDA filings for Ironwood and Forest for linaclotide, and GSK and XenoPort for Horizant ER


US drugmakers Ironwood Pharmaceuticals (Nasdaq: IRWD) and Forest Laboratories (NYSE: FRX) have submitted…

Forest LaboratoriesGastro-intestinalsGlaxoSmithKlineHorizantIronwood PharmaceuticalslinaclotideNeurologicalNorth AmericaPharmaceuticalRegulationXenoPort

Back to top